G. Habets

发表

A role for Rac in Tiaml-induced membrane ruffling and invasion

John G. Collard, F. Michiels, G. Habets, 1995, Nature.

Identification of an invasion-inducing gene, Tiam-1, that encodes a protein with homology to GDP-GTP exchangers for Rho-like proteins

John G. Collard, G. Habets, E. Scholtes, 1994, Cell.

Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma

Kam Y. J. Zhang, K. Flaherty, J. Sosman, 2010, Nature.

Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity

Kam Y. J. Zhang, James Tsai, Nikolas K. Haass, 2008, Proceedings of the National Academy of Sciences.

Design and pharmacology of a highly specific dual FMS and KIT kinase inhibitor

Kam Y. J. Zhang, G. Habets, P. Hirth, 2013, Proceedings of the National Academy of Sciences.

The RUNX1/IL-34/CSF-1R axis is an autocrinally regulated modulator of resistance to BRAF-V600E inhibition in melanoma.

K. Pradhan, J. Sosman, Douglas B. Johnson, 2018, JCI insight.

BRD4 Profiling Identifies Critical Chronic Lymphocytic Leukemia Oncogenic Circuits and Reveals Sensitivity to PLX51107, a Novel Structurally Distinct BET Inhibitor.

Lindsey T. Brinton, J. Byrd, G. Habets, 2018, Cancer discovery.

Structure-Guided Blockade of CSF1R Kinase in Tenosynovial Giant-Cell Tumor.

M. van de Rijn, G. Shapiro, C. Peterfy, 2015, The New England journal of medicine.

Late viral RNA export, rather than p53 inactivation, determines ONYX-015 tumor selectivity.

F. McCormick, G. Habets, L. Johnson, 2004, Cancer cell.

Targeting cells of the myeloid lineage attenuates pain and disease progression in a prostate model of bone cancer

P. Mantyh, G. Habets, J. Tsai, 2015, Pain.

Activation of Rac1 by human Tiam1.

G. Habets, M. Symons, G. Bollag, 2000, Methods in enzymology.

Oncogenic activity of Tiam1 and Rac1 in NIH3T3 cells.

John G. Collard, G. Habets, R. A. van der Kammen, 1995, Oncogene.

Allele‐specific detection of K‐ras oncogene expression in human non‐small‐cell lung carcinomas

S. Rodenhuis, G. Habets, R. Slebos, 2007, International journal of cancer.

RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors.

K. Flaherty, J. Reis-Filho, Qiongqing Wang, 2012, The New England journal of medicine.

Genetic analysis of invasion and metastasis.

John G. Collard, G. Habets, E. Roos, 1988, Cancer surveys.

cDNA array analyses of K-ras-induced gene transcription.

G. Habets, S. Shirasawa, T. Sasazuki, 2001, Methods in enzymology.

RAF inhibitors that evade paradoxical MAPK pathway activation

James Tsai, Ying Zhang, Paul S. Lin, 2015, Nature.

PLX9486 shows anti-tumor efficacy in patient-derived, tyrosine kinase inhibitor-resistant KIT-mutant xenograft models of gastrointestinal stromal tumors

R. Sciot, G. Habets, M. Debiec‐Rychter, 2018, Clinical and Experimental Medicine.

Characterizing and Overriding the Structural Mechanism of the Quizartinib-Resistant FLT3 "Gatekeeper" F691L Mutation with PLX3397.

A. Kasarskis, R. Sebra, A. Bashir, 2015, Cancer discovery.

Role of Tiam 1 in Rac-mediated signal transduction pathways.

John G. Collard, F. Michiels, G. Habets, 1996, Current topics in microbiology and immunology.

Nuclear protein factors and erythroid transcription of the human Aγ-globin gene

F. Grosveld, G. Habets, F. Catala, 1989 .

Genetic Analysis of Invasive and Metastatic Capacity in T Lymphoma Cells

John G. Collard, G. Habets, 1989 .

Sustained microglial depletion with CSF1R inhibitor impairs parenchymal plaque development in an Alzheimer’s disease model

Chao Zhang, Ying Zhang, Wayne Spevak, 2019, Nature Communications.

Induction of invasive and metastatic potential in mouse T-lymphoma cells (BW5147) by treatment with 5-azacytidine

John G. Collard, G. Habets, E. Scholtes, 1990, Clinical & Experimental Metastasis.

Discovery and Development of Vemurafenib: First‐in‐Class Inhibitor of Mutant BRAF for the Treatment of Cancer

G. Habets, G. Bollag, J. Tsai, 2013 .

The human beta‐globin gene contains multiple regulatory regions: identification of one promoter and two downstream enhancers.

F. Grosveld, G. Habets, M. Antoniou, 1988, The EMBO journal.

Scaffold-based discovery of indeglitazar, a PPAR pan-active anti-diabetic agent

Shenghua Shi, Kam Y. J. Zhang, Sarah Will, 2009, Proceedings of the National Academy of Sciences.

Association of Combination of Conformation-Specific KIT Inhibitors With Clinical Benefit in Patients With Refractory Gastrointestinal Stromal Tumors: A Phase 1b/2a Nonrandomized Clinical Trial.

A. Shields, W. Tap, G. Habets, 2021, JAMA oncology.

The Novel Inhibitor PLX3397 Effectively Inhibits FLT3-Mutant AML,

G. Habets, G. Bollag, M. Levis, 2011 .

Interrogating the kinome

Chao Zhang, Gaston Habets, Gideon Bollag, 2011, Nature Biotechnology.

The invasion-inducing TIAM1 gene maps to human chromosome band 21q22 and mouse chromosome 16.

A. Hagemeijer, N. Copeland, D. Gilbert, 1995, Cytogenetics and cell genetics.

Sequence of the human invasion-inducing TIAM1 gene, its conservation in evolution and its expression in tumor cell lines of different tissue origin.

John G. Collard, F. Michiels, G. Habets, 1995, Oncogene.

Abstract 1224: A patient derived xenograft (PDX) platform for development of next generation KIT kinase inhibitors in imatinib-resistant gastrointestinal stromal tumors (GIST)

G. Habets, Thomas B. Broudy, Cyrus Mirsaidi, 2014 .

Structure-Guided Blockade of CSF1R Kinase in Tenosynovial Giant-Cell Tumor.

M. van de Rijn, G. Shapiro, C. Peterfy, 2015, The New England journal of medicine.

The RUNX1/IL-34/CSF-1R axis is an autocrinally regulated modulator of resistance to BRAF-V600E inhibition in melanoma.

K. Pradhan, J. Sosman, E. Bernstein, 2018, JCI insight.

Sublocalization of an invasion-inducing locus and other genes on human chromosome 7.

J. Wiegant, John G. Collard, G. Habets, 1992, Cytogenetics and cell genetics.